Crenolanib (CP-868596) , 98% , 670220-88-9
| Pack Size | Price | Stock | Quantity |
| 5MG | RMB607.20 | In Stock |
|
| 10MG | RMB1151.20 | In Stock |
|
| 25mg | RMB1951.20 | In Stock |
|
| 50MG | RMB3511.20 | In Stock |
|
| 100mg | RMB6319.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Boiling point: | 676.6±65.0 °C(Predicted) |
| Density | 1.36 |
| storage temp. | -20° |
| solubility | Soluble in DMSO (up to 15 mg/ml) or in Ethanol (up to 10 mg/ml). |
| form | solid |
| pka | 9.84±0.20(Predicted) |
| color | White |
| Stability: | Stable for 1 year as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 month. |
| CAS DataBase Reference | 670220-88-9 |
Description and Uses
Crenolanib (670220-88-9) is a potent inhibitor of PDGFR (Kd?for α = 2.1 nM; β = 3.2 nM) and FLT3 (Kd?= 0.74 nM).1?Crenolanib is a type I inhibitor binding only to the active kinase conformation. It showed potent activity against imatinib-resistant PDGFRα mutations D842I, D842V, D842Y, DI842-843M, and deletion I8432?as well as FLT3/ITD and FLT3/D835 mutants3. Crenolanib acted synergistically with FLT3-CAR T-cells in a FLT3-ITD+?AML murine xenograft model.4
Crenolanib (CP-868569) is a highly selective and potent PDGFR-α inhibitor with IC50 of 0.9 and 1.8 nM against PDGFRα and PDGFRβ, respectively.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H315-H319-H335 |
| Precautionary statements | P264-P280-P302+P352-P321-P332+P313-P362-P305+P351+P338-P337+P313-P261-P271-P304+P340-P312-P403+P233-P405-P501 |
